New shot therapy aims to shield Immune-Compromised patients from serious infections
NCT ID NCT04640142
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This study tests a new medicine called Newnorm, given as a shot under the skin, in 50 people aged 2 to 75 with primary immune deficiency (a condition where the immune system is weak). The goal is to see if Newnorm can safely prevent serious bacterial infections and keep antibody levels stable. Participants receive regular doses and are monitored for infections and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE DEFICIENCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Octapharma Research Site
Irvine, California, 92697, United States
-
Octapharma Research Site
Centennial, Colorado, 80112, United States
-
Octapharma Research Site
Hollywood, Florida, 33021, United States
-
Octapharma Research Site
Port Saint Lucie, Florida, 34986, United States
-
Octapharma Research Site
St. Petersburg, Florida, 33701, United States
-
Octapharma Research Site
Chicago, Illinois, 60612, United States
-
Octapharma Research Site
Overland Park, Kansas, 66211, United States
-
Octapharma Research Site
Louisville, Kentucky, 40217, United States
-
Octapharma Research Site
White Marsh, Maryland, 21162, United States
-
Octapharma Research Site
Kansas City, Missouri, 64111, United States
-
Octapharma Research Site
Omaha, Nebraska, 68046, United States
-
Octapharma Research Site
Leipzig, 04129, Germany
-
Octapharma Research Site
Munich, 80337, Germany
-
Octapharma Research Site
Budapest, 1097, Hungary
-
Octapharma Research Site
Debrecen, 4032, Hungary
-
Octapharma Research Site
Naples, 80131, Italy
-
Octapharma Research Site
Roma, 00161, Italy
-
Octapharma Research Site
Roma, 133, Italy
-
Octapharma Research Site
Treviso, 31100, Italy
-
Octapharma Research Site
Krakow, 30-663, Poland
-
Octapharma Research Site
Bratislava, 833 40, Slovakia
-
Octapharma Research Site
Kyiv, 04209, Ukraine
-
Octapharma Research Site
Lviv, 79010, Ukraine
-
Octapharma Research Site
Lviv, 79035, Ukraine
Conditions
Explore the condition pages connected to this study.